Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

2.

Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators.

Lodaya RN, Brito LA, Wu TYH, Miller AT, Otten GR, Singh M, O'Hagan DT.

J Pharm Sci. 2018 Sep;107(9):2310-2314. doi: 10.1016/j.xphs.2018.05.012. Epub 2018 Jun 5.

PMID:
29883663
3.

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.

Wen Y, Trinh HV, Linton CE, Tani C, Norais N, Martinez-Guzman D, Ramesh P, Sun Y, Situ F, Karaca-Griffin S, Hamlin C, Onkar S, Tian S, Hilt S, Malyala P, Lodaya R, Li N, Otten G, Palladino G, Friedrich K, Aggarwal Y, LaBranche C, Duffy R, Shen X, Tomaras GD, Montefiori DC, Fulp W, Gottardo R, Burke B, Ulmer JB, Zolla-Pazner S, Liao HX, Haynes BF, Michael NL, Kim JH, Rao M, O'Connell RJ, Carfi A, Barnett SW.

PLoS One. 2018 Apr 26;13(4):e0194266. doi: 10.1371/journal.pone.0194266. eCollection 2018.

4.

The Preparation and Physicochemical Characterization of Aluminum Hydroxide/TLR7a, a Novel Vaccine Adjuvant Comprising a Small Molecule Adsorbed to Aluminum Hydroxide.

Malyala P, Laera D, Cianetti S, Bufali S, Aggravi M, Ianni E, Judge C, Otten G, Singh M, O'Hagan DT.

J Pharm Sci. 2018 Jun;107(6):1577-1585. doi: 10.1016/j.xphs.2018.01.024. Epub 2018 Feb 6.

PMID:
29421216
5.

Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.

Pepini T, Pulichino AM, Carsillo T, Carlson AL, Sari-Sarraf F, Ramsauer K, Debasitis JC, Maruggi G, Otten GR, Geall AJ, Yu D, Ulmer JB, Iavarone C.

J Immunol. 2017 May 15;198(10):4012-4024. doi: 10.4049/jimmunol.1601877. Epub 2017 Apr 17.

6.

Self-amplifying mRNA vaccines.

Brito LA, Kommareddy S, Maione D, Uematsu Y, Giovani C, Berlanda Scorza F, Otten GR, Yu D, Mandl CW, Mason PW, Dormitzer PR, Ulmer JB, Geall AJ.

Adv Genet. 2015;89:179-233. doi: 10.1016/bs.adgen.2014.10.005. Epub 2014 Dec 4.

PMID:
25620012
7.

The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance.

Shah RR, Dodd S, Schaefer M, Ugozzoli M, Singh M, Otten GR, Amiji MM, O'Hagan DT, Brito LA.

J Pharm Sci. 2015 Apr;104(4):1352-61. doi: 10.1002/jps.24337. Epub 2015 Jan 19.

PMID:
25600347
8.

Rational design of small molecules as vaccine adjuvants.

Wu TY, Singh M, Miller AT, De Gregorio E, Doro F, D'Oro U, Skibinski DA, Mbow ML, Bufali S, Herman AE, Cortez A, Li Y, Nayak BP, Tritto E, Filippi CM, Otten GR, Brito LA, Monaci E, Li C, Aprea S, Valentini S, Calabrό S, Laera D, Brunelli B, Caproni E, Malyala P, Panchal RG, Warren TK, Bavari S, O'Hagan DT, Cooke MP, Valiante NM.

Sci Transl Med. 2014 Nov 19;6(263):263ra160. doi: 10.1126/scitranslmed.3009980.

9.

Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.

Bogers WM, Oostermeijer H, Mooij P, Koopman G, Verschoor EJ, Davis D, Ulmer JB, Brito LA, Cu Y, Banerjee K, Otten GR, Burke B, Dey A, Heeney JL, Shen X, Tomaras GD, Labranche C, Montefiori DC, Liao HX, Haynes B, Geall AJ, Barnett SW.

J Infect Dis. 2015 Mar 15;211(6):947-55. doi: 10.1093/infdis/jiu522. Epub 2014 Sep 18.

10.

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, Archer J, Seubert A, Otten GR, Beard CW, Dey AK, Lilja A, Valiante NM, Mason PW, Mandl CW, Barnett SW, Dormitzer PR, Ulmer JB, Singh M, O'Hagan DT, Geall AJ.

Mol Ther. 2014 Dec;22(12):2118-29. doi: 10.1038/mt.2014.133. Epub 2014 Jul 16.

11.

Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity.

Maruggi G, Shaw CA, Otten GR, Mason PW, Beard CW.

Virology. 2013 Dec;447(1-2):254-64. doi: 10.1016/j.virol.2013.07.021. Epub 2013 Oct 5.

12.

Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, Otten GR, Brazzoli M, Buccato S, Bonci A, Casini D, Maione D, Qi ZQ, Gill JE, Caiazza NC, Urano J, Hubby B, Gao GF, Shu Y, De Gregorio E, Mandl CW, Mason PW, Settembre EC, Ulmer JB, Craig Venter J, Dormitzer PR, Rappuoli R, Geall AJ.

Emerg Microbes Infect. 2013 Aug;2(8):e52. doi: 10.1038/emi.2013.54. Epub 2013 Aug 14.

13.

Generation of a parvovirus B19 vaccine candidate.

Chandramouli S, Medina-Selby A, Coit D, Schaefer M, Spencer T, Brito LA, Zhang P, Otten G, Mandl CW, Mason PW, Dormitzer PR, Settembre EC.

Vaccine. 2013 Aug 20;31(37):3872-8. doi: 10.1016/j.vaccine.2013.06.062. Epub 2013 Jul 2.

PMID:
23827313
14.

Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ.

Cu Y, Broderick KE, Banerjee K, Hickman J, Otten G, Barnett S, Kichaev G, Sardesai NY, Ulmer JB, Geall A.

Vaccines (Basel). 2013 Aug 22;1(3):367-83. doi: 10.3390/vaccines1030367.

15.

The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease.

Shaw CA, Galarneau JR, Bowenkamp KE, Swanson KA, Palmer GA, Palladino G, Markovits JE, Valiante NM, Dormitzer PR, Otten GR.

Vaccine. 2013 Jan 2;31(2):306-12. doi: 10.1016/j.vaccine.2012.11.006. Epub 2012 Nov 12.

PMID:
23153444
16.

Nonviral delivery of self-amplifying RNA vaccines.

Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9. doi: 10.1073/pnas.1209367109. Epub 2012 Aug 20.

17.

MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine.

Singh M, Kazzaz J, Ugozzoli M, Baudner B, Pizza M, Giuliani M, Hawkins LD, Otten G, O'Hagan DT.

Hum Vaccin Immunother. 2012 Apr;8(4):486-90. doi: 10.4161/hv.19229.

PMID:
22832252
18.

Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

Uematsu Y, Vajdy M, Lian Y, Perri S, Greer CE, Legg HS, Galli G, Saletti G, Otten GR, Rappuoli R, Barnett SW, Polo JM.

Clin Vaccine Immunol. 2012 Jul;19(7):991-8. doi: 10.1128/CVI.00031-12. Epub 2012 May 23.

19.

A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding.

Iavarone C, Ramsauer K, Kubarenko AV, Debasitis JC, Leykin I, Weber AN, Siggs OM, Beutler B, Zhang P, Otten G, D'Oro U, Valiante NM, Mbow ML, Visintin A.

J Immunol. 2011 Apr 1;186(7):4213-22. doi: 10.4049/jimmunol.1003585. Epub 2011 Mar 7.

20.

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

Barnett SW, Burke B, Sun Y, Kan E, Legg H, Lian Y, Bost K, Zhou F, Goodsell A, Zur Megede J, Polo J, Donnelly J, Ulmer J, Otten GR, Miller CJ, Vajdy M, Srivastava IK.

J Virol. 2010 Jun;84(12):5975-85. doi: 10.1128/JVI.02533-09. Epub 2010 Apr 14.

Supplemental Content

Loading ...
Support Center